Recent Potential Noninvasive Biomarkers in Necrotizing Enterocolitis

Kewei Wang,1,2 Guozhong Tao,2 Zhen Sun,2 and Karl G. Sylvester2

1Department of Gastrointestinal Surgery, The First Hospital of China Medical University, Shenyang, 110001 Liaoning Province, China
2Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA

Correspondence should be addressed to Karl G. Sylvester; sylvester@stanford.edu

Received 30 October 2018; Revised 31 December 2018; Accepted 12 February 2019; Published 22 April 2019

Academic Editor: Per Hellström

Copyright © 2019 Kewei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Necrotizing enterocolitis (NEC) is a rare but devastating gastrointestinal disease that predominately affects preterm neonates. Numerous studies have revealed that NEC is strongly associated with very low birth weight, degree of prematurity, formula feeding, infection, hypoxic/ischemic injury, and enteric dysbiosis. Given these clinical associations, the search for a deeper understanding of disease pathogenesis has led to an intense interest in the discovery and development of noninvasive biomarkers of NEC from stool, urine, and serum. Biomarkers for NEC may serve at least two general purposes of urgent unmet need: to improve diagnostic accuracy and disease prediction and to reveal the mechanism of the disease. This review will provide an overview of recent research focused on clinical NEC and highlight the advances that were made within the past five years towards the development of noninvasive diagnostic biomarkers.

1. Introduction

All premature infants are at risk of necrotizing enterocolitis (NEC), but incidence and mortality rates differ significantly throughout the world. In the United States alone, the incidence rate for NEC varies between 3 and 10% annually across most series with a mortality of up to 33% [1] and at an estimated cost to the US healthcare system of more than 1 billion dollars [2]. In the United Kingdom (UK), 163 English neonatal departments prospectively collected information on 118,073 newborns over two years and reported on 531 infants (0.4%) who developed severe NEC with a mortality of 48% [3]. In China, the incidence rate of NEC is 4.5% and 2.5% in very low-birth weight (VLBW, birth weight < 1500 g) and low-birth weight (LBW, birth weight < 2500 g) neonates, respectively, and the mortality rate of NEC at stages II and III was 41.7% [4].

The pathogenesis of NEC is incompletely understood and appears to be multifactorial. Current leading models of NEC pathogenesis purport that NEC may initiate due to a maladaptive immune responses to a dysbiotic ecosystem in the preterm gut [5, 6]. Potential risk factors for NEC include very low birth weight [7], prematurity [8], formula feeding [9, 10], hypoxic/ischemic insults [11], infection [12], and microbial dysbiosis [13–15]. Several recent reviews have primarily focused on the pathogenesis of NEC [16, 17]. The clinical diagnosis of NEC is currently made based on a combination of clinical, laboratory, and radiologic findings. The challenge remains the patient’s clinical symptoms, and imaging findings may appear late such that a potential therapeutic window to prevent disease progression may be quite narrow. Therefore, there is an urgent need for identification of noninvasive biomarkers that are suitable for early diagnosis of NEC.
NEC as well as the literature about markers in experimental NEC that did not include an examination of human tissue or samples. This review will highlight these advances in clinical biomarkers of NEC.

2. Biomarkers

The clinical application of biomarkers may include surveillance, early diagnosis, predicting severity and prognosis of disease, or response to therapy. The consensus among experts is that biomarkers may find the greatest immediate utility in providing for an early diagnosis of NEC or for identifying those premature infants most at risk of NEC prior to overt clinical manifestations. The rationale for this framework is that early or preclinical disease recognition will provide the greatest possible opportunity for disease prevention or mitigation. Since the intestine and colon cannot be directly sampled, research has focused on the development of noninvasive measures for NEC biomarkers [18]. From a practical perspective, there are multiple approaches to noninvasive interrogation including the sampling of neonatal stool, urine, and serum (Figure 1). The most expansive experience has been acquired among studies that have utilized fecal, urine, or serum biomarkers that can contribute to the diagnosis of NEC [19]. Herein, we provide for a review of the more promising noninvasive biomarker descriptions from the past five years and include a description of their biologic relevance and possible clinical utility that is summarized in Table 1.

2.1. Biomarkers in Stool

2.1.1. Calprotectin. Increased fecal calprotectin indicates the increased presence of neutrophils in the intestinal epithelium, which can occur during intestinal inflammation. Prior studies have found that an increase in calprotectin in the preterm neonate is associated with an early diagnosis of NEC and prediction of disease severity [20–22]. Bin-Nun et al. measured fecal calprotectin in neonates with a clinical suspicion of NEC using a rapid calprotectin assay. The authors calculated a cut-off value (480 μg/g) of fecal calprotectin that gave a maximum sum of diagnostic sensitivity and specificity (sensitivity 100% and specificity 84.6%) [23]. Pergialiotis et al. conducted a systematic review of fecal calprotectin levels as a noninvasive marker for NEC. This review included 13 studies of 601 neonates and showed that the sensitivity and specificity of fecal calprotectin as a diagnostic marker were 76–100% and 39–96.4%, respectively [24]. However, other scholars have reported no difference in fecal calprotectin levels between NEC and control groups and further concluded that fecal calprotectin would not be useful for early NEC diagnosis given large individual variation in fecal levels [25]. Therefore, more data is needed to determine whether a sudden increase in fecal calprotectin can be used as a diagnostic or prognostic biomarker before clinical symptoms occur. Results from recent research showed that 62% of preterm neonates have a high baseline calprotectin (≥200 μg/g) level throughout the first week after birth [26]. There were also a significant positive linear relationship in the gestational age < 26 weeks group and a significant negative linear relationship in the gestational age ≥ 26 weeks and <30 weeks group between the fecal calprotectin concentration and days after birth [27]. Stool from preterm neonates has a higher range of calprotectin than stool from term neonates. Thus, a calprotectin upper reference interval that incorporates corrected gestational age may help in predicting the onset of NEC more accurately [28]. In summary, fecal calprotectin may be an effect biomarker to screen for NEC among subsets of at-risk neonates. However, since calprotectin is an inflammatory marker and therefore not specific for NEC, an approach combining it with other composite measures may increase its specificity. Additional prospective well-controlled trials are needed to verify utility and increase specificity.

2.1.2. Microbiota. In recent years, microbiota has been found to be crucial for metabolic, hormonal, and immunologic homeostasis of their hosts. Microbial composition of stool is different between NEC and non-NEC cases, with a greater abundance of Proteobacteria among NEC infants [29]. The samples used for analysis were obtained before the diagnosis of NEC. These results were not therefore affected by the therapeutic effect (antibiotics) and can more accurately reflect microbial composition preceding a diagnosis. Still, the precise contribution to NEC pathophysiology remains ambiguous. There was an increase in total bacterial count (9.8-fold) in affected newborns 24 hours before the occurrence of clinical manifestations of NEC primarily due to the expansion of E. coli species (21.6-fold). However, intriguingly, the microbiota composition did not significantly differ from that of extremely low-birth weight (ELBW) neonates 5 days before the occurrence of NEC [30]. These results suggest that if the total number of bacteria increases significantly, the newborn may suffer from NEC within a short period. Currently, it is unknown if this type of assessment can have practical clinical applications given several technical and biologic limitations.

2.1.3. Fecal Volatile Organic Compounds (VOCs). Fecal VOCs may reflect not only gut microbiota composition but
| Biomarker name | Usefulness in predicting NEC | Usefulness in differential diagnosis | Sensitivity | Specificity | Refs. | Comments |
|----------------|-------------------------------|--------------------------------------|--------------|------------|-------|----------|
| **Biomarker in stool** | | | | | | |
| Calprotectin | 281 μg/g, early diagnosis and prediction of severity | NEC vs. sepsis | 88.24% | 82.61% | 20 | (i) Inflammatory marker, not specific for NEC |
| | 480 μg/g | | 100% | 84.6% | 23 | |
| | 226 μg/g, 299 μg/g (GA < 35 w) | | 75%, 71% | 76%, 88% | 28 | (ii) High individual variability |
| VOCs | Early prediction of NEC | NEC vs. sepsis | 83% | 75% | 32 | (iii) Larger samples will be required |
| **Biomarker in urine** | | | | | | |
| I-FABPu | 10.2 pg/nmol cr, early prediction of NEC | NEC vs. sepsis | 100% | 95.6% | 35 | |
| | 2.52 pg/nmol cr | | 81% | 100% | 36 | |
| | 218 ng/ml (0-8 h after the onset of symptoms) | Uncomplicated vs. complicated NEC, 232 ng/ml (8-16 h after the onset of symptoms) | 57%, 71% | 89%, 80% | 46 | |
| Urinary SAA | | | 34.4 ng/ml, medical vs. surgical NEC | 83% | 83% | 40 | |
| PGE-MUM | Severity of NEC | | 92.3% | 81.5% | 41 | (ii) Not specific for NEC |
| Urinary proteins | CST3, PEDF, and RET4: severity of NEC | A2ML1, CD14, CST3, PEDF, RET4, and VASN: NEC vs. sepsis | 89% | 80% | 43 | (iii) High cost |
| | | | 89% | 90% | | |
| **Biomarker in serum** | | | | | | |
| I-FABPp | Severity of NEC | Medical vs. surgical NEC | 64% | 91% | 39 | (i) Medium sensitivity |
| | 9 ng/ml (0-8 h after the onset of symptoms) | Uncomplicated vs. complicated NEC, 19 ng/ml (8-16 h after the onset of symptoms) | 80%, 88% | 86%, 80% | 46 | |
| | Early diagnosis | | 67%, 74%, 0.83% | 84% | 47 | |
| Fibrinogen-γ dimers | Severity of NEC | NEC vs. sepsis | | | 49 | |
| IMA | Severity of NEC | 252.57 pmol/ml, medical vs. surgical NEC | 89.5% | 64% | 50 | (ii) Not specific for NEC from other ischemic diseases |
| | | 294.91 pmol/ml, survival vs. died infants | 92.9% | 96.7% | | |
| Interleukin-8 | Severity of NEC | 1783 pg/ml, medical vs. surgical NEC | 90.5% | 59.2% | 52 | (iii) Nonspecific marker of systemic inflammation |
| IaIp | 207 mg/l | Spontaneous intestinal perforation | 100% | 88.2% | 54 | (iv) Larger samples will be required |
| **Other noninvasive markers** | | | | | | |
| NIRS | Uncomplicated vs. complicated NEC | | | | 56 | (i) No distinction between NEC and other intestinal diseases during the early stages |
also their metabolic activity and interaction with the host. Identification of “disease-specific” VOCs may increase the understanding of pathophysiological mechanisms and may assist in the development of a useful biomarker [31]. A recent study showed that fecal VOCs of infants with NEC are significantly different from those of nonill infants and infants with sepsis 2 or 3 days prior to the occurrence of clinical manifestations of NEC [32]. These findings, while offering a potentially compelling new line of investigation, included only 13 samples from each group, thus indicating the need and necessity to expand the sample size further to verify its efficacy as a biomarker for NEC.

2.2. Biomarkers in Urine. Due to its rich source of peptides and proteins, urine may contain many potential biomarkers that can be easily and noninvasively collected [33].

2.2.1. Intestinal Fatty Acid-Binding Protein (I-FABP). I-FABP is one of the most widely studied potential biomarkers of NEC. I-FABP is released into the bloodstream upon intestinal injury and is excreted by the kidneys. Thus, I-FABP can be detected in either blood or urine as a potential biomarker of intestinal mucosal damage caused by NEC [34]. Gollin et al. reported that elevated I-FABPu (in urine) was a sensitive and specific predictive biomarker for NEC one day before clinical manifestations [35]. Levels of urinary I-FABP are higher in NEC patients than in sepsis patients or healthy infants with a sensitivity of 81% and a specificity of 100% [36]. It has also been observed that the length of intestinal resection in surgical NEC was closely related to serum or urinary I-FABP levels at the occurrence of the disease [37]. Moreover, I-FABPu correlated significantly with serum IL-6 and lactate during the first eight hours of the disease [38]. Together, these results suggest that I-FABP may be a clinically valid biomarker for NEC in the future. But a recent meta-analysis of evaluating the role of I-FABP in the diagnosis of NEC reported that the sensitivities of urinary I-FABP and the I-FABP/Cr ratio for NEC were 64% and 78% and the specificities were 73% and 75%, respectively [39]. These results showed a low sensitivity and specificity of urinary I-FABP for NEC. Thus, there are still a lot of works that we need to do to improve its accuracy.

2.2.2. Serum Amyloid A (SAA). SAA is an acute-phase protein, rapidly synthesized by the liver and kidneys following the induction by proinflammatory cytokines. Several studies have examined levels of SAA and its association with NEC. A recent study revealed that urinary SAA may be a potential marker in distinguishing severe NEC, particularly when applied in combination with serum platelet count. An optimized cut-off value of SAA of 40.7 ng/ml was identified for the stage II and stage III NEC group by Bells’ modified criteria. A cut-off value between surgical and medical NEC was determined at 34.4 ng/ml with a sensitivity of 83% and a specificity of 83%. This same group also reported that the combination of urinary SAA and serum platelet count could increase the identification sensitivity to 94% [40]. These results suggest that urinary SAA may be a potential marker in distinguishing severe NEC, particularly when applied in combination with serum platelet count.

2.2.3. Prostaglandin E2 Major Urinary Metabolite (PGE-MUM). PGE-MUM was recently reported as a possible urine biomarker of NEC given its high stability in urine. The median PGE-MUM value was highest in the NEC group (576 μg/g Cre/BSA × 1000), followed by the other disease group (94 μg/g Cre/BSA × 1000) and the healthy infant group (19 μg/g Cre/BSA × 1000) (sensitivity: 92.3%, specificity: 81.5%; p < 0.01). In addition, PGE-MUM level was associated with the length of necrotic intestine and Bell’s staging criteria [41]. PGE-MUM is also a biomarker of intestinal mucosal inflammation and can reflect the severity of pediatric ulcerative colitis [42]. Similar to calprotectin, PGE-MUM is not specific for NEC, thus indicating the need for

| Biomarker name | Usefulness in predicting NEC | Usefulness in differential diagnosis | Sensitivity | Specificity | Refs. | Comments |
|---------------|-----------------------------|--------------------------------------|-------------|------------|-------|----------|
| Doppler flow velocity | Necrosis vs. sepsis | Cerebral rSO2 ≤ 71%, liver rSO2 ≤ 59% | 100%, 100% | 80%, 100% | 57 | (ii) Not specific for NEC from other ischemic diseases |
| HRV | Severity of NEC (stage II vs. stage III) | RI > 0.75, PI > 1.85 | 96.3%, 88.8% | 90.9%, 78.8% | 58 | (iii) Stability of HF-HRV requires more verification |
| Gene polymorphisms | Severity of NEC | 4.68 ms² HF-HRV | 89% | 87% | 60 | (iv) Long time to obtain the results |

NEC: necrotizing enterocolitis; Ref: reference; GA: gestational age; VOCs: volatile organic compounds; I-FABP: intestinal fatty acid-binding protein; SAA: serum amyloid A; PGE-MUM: prostaglandin E major urinary metabolite; CST3: cystatin 3; PEDF: pigment epithelium-derived factor; RET4: retinol-binding protein 4; A2ML1: alpha-2-macroglobulin-like protein 1; CD14: cluster of differentiation protein 14; VASN: vasolin; IaIp: inter-alpha inhibitor protein; IGFBP: insulin-like growth factor binding protein 4; Gollin et al. reported that elevated I-FABPu (in urine) was a marker of intestinal mucosal damage caused by NEC [34].
additional study and exploration of possible utility when combined with other markers.

2.2.4. Urinary Proteins. Liquid chromatography/mass spectrometry and enzyme-linked immunosorbent assay have been used to discover and validate various candidate biomarkers of NEC utilizing urine as a substrate. Seven urinary proteins, cluster of differentiation protein 14 (CD14), alpha-2-macroglobulin-like protein 1 (A2ML1), pigment epithelium-derived factor (PEDF), cystatin 3 (CST3), retinol-binding protein 4 (RET4), fibrinogen alpha chain (FGA), andvasolin, were utilized in various combinations to determine the presence or severity of the disease [43]. A panel consisting of A2ML1, CD14, CST3, PEDF, RET4, and VASN produced an area under the curve (AUC) of 98.4% for distinguishing medical and surgical NEC, and a panel consisting of CST3, PEDF, and RET4 produced an AUC of 98.2% for distinguishing NEC from sepsis. Together, these results suggest that NEC may be associated with several protein aberrations, and composite panels of proteins may have greater classifying capabilities than single analytes.

2.3. Biomarkers in Serum

2.3.1. I-FABP. I-FABP exists exclusively in epithelial cells in the mucosal layer of the small intestine [44]. When intestinal epithelial cells are damaged, I-FABP proteins are released into the bloodstream. A recent longitudinal study of I-FABP compared three groups with 45 infants in each group: NEC patients, non-NEC patients, and healthy newborns. This study showed that the level of I-FABP at each time point of NEC was remarkably higher than that of the non-NEC group and the level was lowest in healthy newborns [45]. I-FABP levels are highest in the first 8 hours after symptoms occur and gradually decline with time. A cut-off value of I-FABP for NEC was determined to be 9 ng/ml in plasma and 218 ng/ml in urine 0-8 h after the onset of symptoms, and that for severe NEC was 19 ng/ml in plasma and 232 ng/ml in urine 8-16 h after the onset of symptoms [46]. Together, these results demonstrate that the level of I-FABP is dynamic, undergoing change in all groups with variability depending on the stage and time of disease diagnosis. Therefore, serum I-FABP levels and their changes may be suitable markers of early diagnosis and prognosis of NEC. There have been several meta-analyses of serum I-FABP. Yang et al. reported a sensitivity of serum I-FABP of 64% and 71% and a specificity of 91% and 76% for NEC and surgical NEC, respectively [39]. Another meta-analysis showed that the pooled sensitivity of I-FABP was 0.67 for NEC I, 0.74 for NEC II, and 0.83 for NEC III, and the pooled specificity was 0.84, respectively [47]. In summary, serum I-FABP has high specificity in the diagnosis of NEC and is a promising biomarker, but its limitation is its moderate sensitivity. Therefore, additional analytes appear to be needed to improve the sensitivity of serum I-FABP.

2.3.2. Fibrinogen-γ Dimers. Fibrinogen-γ dimers and coagulant factor XIII play an important role in the prevention of blood loss and initiation of wound healing [48]. Impaired intestinal epithelial healing is a key factor in the pathogenesis of NEC. By comparing the plasma of NEC, sepsis, and healthy infants from nine institutions, Tao et al. discovered that fibrinogen-γ dimers were absent in patients with NEC [49]. These results provided a highly significant difference between sepsis and NEC infants (AUC = 0.958) as well as between healthy and NEC infants (AUC = 0.91). Importantly, this result was mechanistically demonstrated to be caused by a severe impairment in blood coagulant factor XIII, which covalently cross-links two molecules of fibrinogen-γ to produce the dimer. The levels of factor XIII were found to be lower in NEC plasma (6.56 ± 2.21 μg/ml) compared with healthy infants (13.55 ± 5.38 μg/ml) or the sepsis cohort (9.63 ± 4.49 μg/ml). Further, the authors showed that by replacing factor XIII in NEC plasma, the FGG returned to non-NEC levels, thus providing the mechanistic understanding for the reduction in FGG dimer in NEC plasma.

2.3.3. Ischemia-Modified Albumin (IMA). Intestinal ischemia has historically been linked to the development of NEC. Under hypoxia-ischemia condition, the N-terminal amino acids of human serum albumin (HAS) are altered resulting in reduced binding capacity. Levels of this modified albumin IMA were found to be significantly higher in infants with stage III NEC than in infants with stage II NEC on the first, third, and seventh days (p < 0.001) [50]. IMA was also found to be superior to CRP and IL-6 in both diagnosis and follow-up of NEC progression. However, IMA has a relationship with other ischemia-related conditions, such as acute coronary syndrome and ischemia of the liver, brain, kidney, and bowel. These associations signify the lack of specificity of IMA and therefore limit the ability of IMA to distinguish NEC from these diseases.

2.3.4. Interleukin-8 (IL-8). IL-8 can be secreted by several types of cells with Toll-like receptors that are involved in the innate immune response. Benkoe et al. reported that IL-8 was significantly higher in infants with NEC compared with controls and provided a diagnostic value with an AUC of 0.99 [51]. In addition, the level of IL-8 was shown to predict the 60-day mortality in premature neonates with NEC [52]. As with most inflammatory markers that have been associated with NEC, the limitation of IL-8 is that it is a nonspecific marker for systemic inflammation, not specific to NEC.

2.3.5. Inter-Alpha Inhibitor Protein (IaIp). IaIp is considered a negative acute-phase protein that protects against the damaging effects of proteases released during acute systemic inflammation [53]. The mean IaIp levels in blood were significantly lower in infants with NEC compared with infants with spontaneous intestinal perforation (SIP) (p < 0.05). ROC analysis for NEC yielded an AUC of 0.98 with a sensitivity of 100% and a specificity of 88.2% (<207 mg/l) [54]. A limitation of this study was the modest sample size. The need remains to expand the sample size to verify the accuracy and stability of IaIp for predicting NEC.

2.3.6. Acylcarnitines. A recent population-based study by Sylvester et al. examined metabolic screening data of 94110 preterm neonates born in California from 2005 to 2008 [55]. All
neonates included in this study had acylcarnitine measurement in birth hospitals between 12 hours and 8 days after birth. Fourteen acylcarnitine levels and ratios were found to be significantly associated with an increased risk of developing NEC upon univariate analysis. When patient characteristics and acylcarnitine levels and ratios were assessed together, five acylcarnitine levels (log C5, log C5:1, log C8:1, log C12, and log C14:1) and one acylcarnitine ratio (log FC/(C16 + C18 : 1)) were found to be significantly associated with NEC (AUC = 0.958, p < 0.05). Since acylcarnitine levels are derived from the metabolism of fatty and organic acids, the authors concluded that abnormal fatty acid metabolism was related to prematurity and the onset of NEC.

2.4. Other Noninvasive Markers to Predict NEC

2.4.1. Near-Infrared Spectroscopy (NIRS). As mentioned above, intestinal ischemia may be one of the causative factors of NEC that results in low regional tissue oxygen saturation (rSO2). NIRS measures rSO2 noninvasively. In a recent study, a continuous cerebral rSO2 ≤ 71% in the first eight hours after the occurrence of symptoms predicted the development of complicated NEC (Bell’s stage 3B or death) with a sensitivity of 100% and a specificity of 80%. In this same study, the liver rSO2 ≤ 59% had a similar effect with a sensitivity of 100% and a specificity of 100%. However, NIRS monitoring did not distinguish between NEC and other intestinal diseases during the early stages of the disease [56].

2.4.2. Doppler Flow Velocity. Doppler ultrasonography and flowmetry of the superior mesenteric arteries can measure the peak systolic velocity (PSV), end-diastolic velocity (EDV), resistivity index (RI), and pulsatility index (PI). Several recent publications recently demonstrated statistically significantly lower PSV (p = 0.001) and EDV (p = 0.001) in a sepsis cohort with clinical signs of NEC [57] and higher RI and PI in NEC patients compared to a control group [58]. These results suggest that intestinal blood flow ultrasonography may be a useful tool for predicting or diagnosing NEC. But like markers of ischemia discussed above, Doppler flow velocity is not specific to NEC compared with other ischemic diseases and clinical conditions that may alter intestinal blood flow patterns.

2.4.3. Heart Rate Variability (HRV). HRV can reflect the autonomic tone of neonates. It was quantified by retrieving archived electrocardiogram (EKG) data. HRV metrics showed a depression of autonomic tone that preceded the clinical NEC onset by 2 days. The pattern of HRV change was also significantly associated with the clinical severity of NEC (stage II vs. stage III) [59]. Doheny et al. conducted a prospective study using high-frequency (HF) component of heart rate variability (HRV) in the first week of life in premature infants to evaluate the utility of HF-HRV in predicting NEC. The HF-HRV power was 21.5 ± 2.7 and 3.9 ± 0.81 ms² in infants that remained healthy and those that subsequently developed stage 2+ NEC, respectively (p < 0.001). The cut-off value of HF-HRV that predicted NEC was 4.68 ms² with a sensitivity and specificity of 89% and 87%, respectively, and a positive and negative predictive value of 50% and 98%, respectively. These results suggest that low vagal tone (low HF power) in the first week of life in premature neonates may be a contributor for predicting the subsequent onset of NEC [60]. However, the HRV may be affected by many other conditions, such as feeding or pain. Therefore, the stability of HF-HRV for clinical application in NEC requires additional verification.

2.4.4. Gene Polymorphisms. Gene polymorphisms are associated with many diseases including NEC. The rs1048719 polymorphism in the intron region of the GM2 activator (GM2A) gene and the rs2075783 polymorphism in the exon 1 region have been reported in association with NEC [61]. Furthermore, the rs11465996 polymorphism in the promoter region of the myeloid differential protein-2 (MD-2) gene was found to be associated with the severity of NEC. By comparing the frequency of SIGIRR variants in NEC infants to that in 20 premature infants without NEC, Sampath et al. found more SIGIRR variants in infants with NEC [62]. It remains unclear whether these associations have sufficient precision or strength of association to provide clinical utility. Moreover, since it takes a long time to obtain the results of genetic polymorphism detection, high-risk newborns should be tested shortly after birth rather than when suspected of developing NEC to compensate for time to actionable information limitation.

Although significant progress has been made in the study of NEC biomarkers, the supporting data for their clinical use remain insufficient [63], and the use of biomarkers alone to predict the risk of NEC remains of insufficient accuracy. Therefore, many scholars continue to pursue more accurate prediction models and methods. The combination of clinical parameters with biomarker analysis may significantly improve our ability to identify individuals at risk of developing NEC [64]. Since most of the existing published works on noninvasive markers provide indirect evidence of NEC, most of them do not directly reflect the degree of damage of intestinal epithelial cells. Additional progress is likely to come from a combination of markers and modalities, e.g., ultrasound and plasma or stool biomarker. Still, NEC biomarker studies to date have provided a significant increase in our understanding of its basic biology and associated pathophysiology.

3. Conclusions

Necrotizing enterocolitis is one of the most severe acquired diseases affecting preterm neonates. Early diagnosis remains elusive which continues to prompt human subject studies in the search for NEC-associated biomarkers that may provide for early diagnosis or the recognition of high-risk subcohorts with sufficient precision to facilitate preventive measures.

Conflicts of Interest

The authors have declared that there is no conflict of interest.
References

[1] S. C. Fitzgibbons, Y. Ching, D. Yu et al., "Mortality of necrotizing enterocolitis expressed by birth weight categories," *Journal of Pediatric Surgery*, vol. 44, no. 6, pp. 1072–1076, 2009.

[2] S. J. McElroy, "Unraveling the enigma that is neonatal necrotizing enterocolitis," *Journal of Perinatology*, vol. 34, no. 10, pp. 729–730, 2014.

[3] C. Battersby, N. Longford, S. Mandalia, K. Costeloe, N. Modi, and UK Neonatal Collaborative Necrotising Enterocolitis (UKNC-NEC) study group, "Incidence and enteral feed antecedents of severe neonatal necrotising enterocolitis across neonatal networks in England, 2012–13: a whole-population surveillance study," *The Lancet Gastroenterology & Hepatology*, vol. 2, no. 1, pp. 43–51, 2017.

[4] T. Qian, R. Zhang, L. Zhu et al., "Necrotizing enterocolitis in low birth weight infants in China: mortality risk factors expressed by birth weight categories," *Pediatrics and Neonatology*, vol. 58, no. 6, pp. 509–515, 2017.

[5] S. M. Tanner, T. F. Berryhill, J. L. Ellenburg et al., "Pathogenesis of necrotizing enterocolitis: modeling the innate immune response," *The American Journal of Pathology*, vol. 185, no. 1, pp. 4–16, 2015.

[6] T. L. Denning, A. M. Bhatia, A. F. Kane, R. M. Patel, and P. W. Denning, "Pathogenesis of NEC: role of the innate and adaptive immune response," *Seminars in Perinatology*, vol. 41, no. 1, pp. 15–28, 2017.

[7] B. J. Stoll, N. I. Hansen, E. F. Bell et al., "Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012," *Journal of the American Medical Association*, vol. 314, no. 10, pp. 1039–1051, 2015.

[8] K. Sankaran, B. Puckett, D. S. Lee et al., "Variations in incidence of necrotizing enterocolitis in Canadian neonatal intensive care units," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 39, no. 4, pp. 366–372, 2004.

[9] M. Good, C. P. Sodhi, and D. J. Hackam, "Evidence-based feeding strategies before and after the development of necrotizing enterocolitis," *Expert Review of Clinical Immunology*, vol. 10, no. 7, pp. 875–884, 2014.

[10] D. J. C. Berkhout, P. Klaassen, H. J. Niemarkt et al., "Risk factors for necrotizing enterocolitis: a prospective multicenter case-control study," *Neonatology*, vol. 114, no. 3, pp. 277–284, 2018.

[11] Y. Yu, C. Klemann, X. Feng et al., "Increased inflammatory reaction to intestinal ischemia-reperfusion in neonatal versus adult mice," *European Journal of Pediatric Surgery*, vol. 25, no. 1, pp. 46–50, 2015.

[12] S. Eaton, C. M. Rees, and N. J. Hall, "Current research on the epidemiology, pathogenesis, and management of necrotizing enterocolitis," *Neonatology*, vol. 111, no. 4, pp. 423–430, 2017.

[13] T. G. Elgin, S. L. Kern, and S. J. McElroy, "Development of the neonatal intestinal microbiome and its association with necrotizing enterocolitis," *Clinical Therapeutics*, vol. 38, no. 4, pp. 706–715, 2016.

[14] B. B. Warner, E. Deych, Y. Zhou et al., "Gut bacteria dysbiosis and necrotising enterocolitis in very low birthweight infants: a prospective case-control study," *Lancet*, vol. 387, no. 10031, pp. 1928–1936, 2016.

[15] J. Neu and M. Pammi, "Pathogenesis of NEC: impact of an altered intestinal microbiome," *Seminars in Perinatology*, vol. 41, no. 1, pp. 29–35, 2017.

[16] A. Gupta and A. Paria, "Etiology and medical management of NEC," *Early Human Development*, vol. 97, pp. 17–23, 2016.

[17] D. F. Niño, C. P. Sodhi, and D. J. Hackam, "Necrotizing enterocolitis: new insights into pathogenesis and mechanisms," *Nature Reviews. Gastroenterology & Hepatology*, vol. 13, no. 10, pp. 590–600, 2016.

[18] L. Nantais-Smith and M. Kadrofske, "Noninvasive biomarkers of necrotizing enterocolitis," *The Journal of Perinatal & Neonatal Nursing*, vol. 29, no. 1, pp. 69–80, 2015.

[19] P. C. Ng, T. P. Y. Ma, and H. S. Lam, "The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis," *Archives of Disease in Childhood - Fetal and Neonatal Edition*, vol. 100, no. 5, pp. F448–F452, 2015.

[20] E. A. Albanna, H. S. Ahmed, and H. A. Awad, "Stool calprotectin in necrotizing enterocolitis," *Journal of Clinical Neonatology*, vol. 3, no. 1, pp. 16–19, 2014.

[21] B. C. MacQueen, R. D. Christensen, C. C. Yost et al., "Elevated fecal calprotectin levels during necrotizing enterocolitis are associated with activated neutrophils extruding neutrophil extracellular traps," *Journal of Perinatology*, vol. 36, no. 10, pp. 862–869, 2016.

[22] M. Zhang, X. Zhang, and J. Zhang, "Diagnostic value of fecal calprotectin in preterm infants with necrotizing enterocolitis," *Clinical Laboratory*, vol. 62, no. 5, pp. 863–869, 2016.

[23] A. Bin-Nun, C. Booms, N. Sabag, R. Mevorach, N. Algur, and C. Hammerman, "Rapid fecal calprotectin (FC) analysis: points of care testing for diagnosing early necrotizing enterocolitis," *American Journal of Perinatology*, vol. 32, no. 4, pp. 337–342, 2014.

[24] V. Pergialiotis, P. Konstantopoulos, N. Karampetsou et al., "Calprotectin levels in necrotizing enterocolitis: a systematic review of the literature," *Inflammation Research*, vol. 65, no. 11, pp. 847–852, 2016.

[25] A. G. J. F. van Zoonen, C. V. Hulzebos, A. C. Muller Kobold, E. M. W. Kooi, A. F. Bos, and J. B. F. Hulscher, "Serial fecal calprotectin in the prediction of necrotizing enterocolitis in preterm neonates," *Journal of Pediatric Surgery*, vol. 54, no. 3, pp. 455–459, 2019.

[26] W. Nakayuenyongsuk, M. Christo, D. K. Stevenson, K. Sylvester, H. C. Lee, and K. T. Park, "Point-of-care fecal calprotectin monitoring in preterm infants at risk for necrotizing enterocolitis," *The Journal of Pediatrics*, vol. 196, pp. 98–103.e1, 2018.

[27] J. M. Yoon, J. Y. Park, K. O. Ko, J. W. Lim, E. J. Cheon, and H. J. Kim, "Fecal calprotectin concentration in neonatal necrotizing enterocolitis," *Korean Journal of Pediatrics*, vol. 57, no. 8, pp. 351–356, 2014.

[28] B. C. MacQueen, R. D. Christensen, C. C. Yost et al., "Reference intervals for stool calprotectin in preterm neonates and their utility for the diagnosis of necrotizing enterocolitis," *Journal of Perinatology*, vol. 38, no. 10, pp. 1379–1385, 2018.

[29] T. P. Lindberg, M. J. Caimano, J. I. Hagadorn et al., "Preterm infant gut microbial patterns related to the development of necrotizing enterocolitis," *The Journal of Maternal-Fetal & Neonatal Medicine*, pp. 1–10, 2018.

[30] A. C. Jenke, J. Postberg, B. Mariel et al., "$S100A12$ and hBD2 correlate with the composition of the fecal microflora in ELBW infants and expansion of *E. coli* is associated with NEC," *BioMed Research International*, vol. 2013, Article ID 150372, 8 pages, 2013.
[31] D. J. C. Berkhout, H. J. Niemierck, N. K. H. de Boer, M. A. Benninga, and T. G. J. de Meij, “The potential of gut microbiota and fecal volatile organic compounds analysis as early diagnostic biomarker for necrotizing enterocolitis and sepsis in preterm infants,” Expert Review of Gastroenterology & Hepatology, vol. 12, no. 5, pp. 457–470, 2018.

[32] T. G. J. de Meij, M. P. C. van der Schee, D. J. C. Berkhout et al., “Early detection of necrotizing enterocolitis by fecal volatile organic compounds analysis,” The Journal of Pediatrics, vol. 167, no. 3, pp. 562–567.e1, 2015.

[33] K. G. Sylvester and R. L. Moss, “Urinary biomarkers for necrotizing enterocolitis,” Pediatric Surgery International, vol. 31, no. 5, pp. 421–429, 2015.

[34] J. P. M. Derikx, N. J. Evennett, P. L. J. Degraeuwe et al., “Urinary based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis,” Gut, vol. 56, no. 10, pp. 1473–1475, 2007.

[35] G. Gollin, D. Stadie, J. Mayhew et al., “Early detection of impending necrotizing enterocolitis with urinary intestinal fatty acid-binding protein,” Neonatology, vol. 106, no. 3, pp. 195–200, 2014.

[36] S. Coufal, A. Kokesova, H. Taslakova-Hogenova, J. Snajdalf, M. Rygl, and M. Kverka, “Urinary intestinal fatty acid-binding protein can distinguish necrotizing enterocolitis from sepsis in early stage of the disease,” Journal of Immunology Research, vol. 2016, Article ID 5727312, 8 pages, 2016.

[37] F. H. Heida, J. B. F. Hulscher, M. Schurink et al., “Intestinal fatty acid-binding protein levels in necrotizing enterocolitis correlate with extent of necrotic bowel: results from a multicenter study,” Journal of Pediatric Surgery, vol. 50, no. 7, pp. 1115–1118, 2015.

[38] M. Schurink, I. G. H. Scholten, E. M. W. Kooi et al., “Intestinal fatty acid-binding protein in neonates with imminent necrotizing enterocolitis,” Neonatology, vol. 106, no. 1, pp. 49–54, 2014.

[39] G. Yang, Y. Wang, and X. Jiang, “Diagnostic value of intestinal fatty-acid-binding protein in necrotizing enterocolitis: a systematic review and meta-analysis,” Indian Journal of Pediatrics, vol. 83, no. 12-13, pp. 1410–1419, 2016.

[40] K. W. Reisinger, B. W. Kramer, D. C. Van der Zee et al., “Non-invasive serum amyloid A (SAA) measurement and plasma platelets for accurate prediction of surgical intervention in severe necrotizing enterocolitis (NEC),” PLoS One, vol. 9, no. 3, article e90834, 2014.

[41] K. I. Konishi, M. Yoshida, A. Nakao et al., “Prostaglandin E-major urinary metabolite as a noninvasive surrogate marker for infantile necrotizing enterocolitis,” Journal of Pediatric Surgery, 2018.

[42] S. I. Hagiwara, I. Okayasu, M. Fujiiwara et al., “Prostaglandin E-major urinary metabolite as a biomarker for pediatric ulcerative colitis activity,” Journal of Pediatric Gastroenterology and Nutrition, vol. 64, no. 6, pp. 955–961, 2017.

[43] K. G. Sylvester, X. B. Ling, G. Y.-G. Liu et al., “Urine protein biomarkers for the diagnosis and prognosis of necrotizing enterocolitis in infants,” The Journal of Pediatrics, vol. 164, no. 3, pp. 607–612.e7, 2014.

[44] R. K. Ockner and J. A. Manning, “Fatty acid-binding protein in small intestine. Identification, isolation, and evidence for its role in cellular fatty acid transport,” The Journal of Clinical Investigation, vol. 54, no. 2, pp. 326–338, 1974.

[45] Z. Li and L. Sheng, “Significance of dynamic evolution of TNF-a, IL-6 and intestinal fatty acid-binding protein levels in neonatal necrotizing enterocolitis,” Experimental and Therapeutic Medicine, vol. 15, no. 2, pp. 1289–1292, 2017.

[46] M. Schurink, E. M. W. Kooi, C. V. Hulzebos et al., “Intestinal fatty acid-binding protein as a diagnostic marker for complicated and uncomplicated necrotizing enterocolitis: a prospective cohort study,” PLoS One, vol. 10, no. 3, article e0121336, 2015.

[47] S. Cheng, J. Yu, M. Zhou, Y. Tu, and Q. Lu, “Serologic intestinal-fatty acid binding protein in necrotizing enterocolitis diagnosis: a meta-analysis,” BioMed Research International, vol. 2015, Article ID 1567904, 8 pages, 2015.

[48] V. Schroeder and H. P. Kohler, “New developments in the area of factor XIII,” Journal of Thrombosis and Haemostasis, vol. 11, no. 2, pp. 234–244, 2013.

[49] G. Z. Tao, B. Liu, R. Zhang et al., “Impaired activity of blood coagulant factor XIII in patients with necrotizing enterocolitis,” Scientific Reports, vol. 5, no. 1, article 13119, 2015.

[50] I. Yakut, C. Tayman, O. Oztekin, M. Namslu, F. Karaca, and A. Kosus, “Ischemia-modified albumin may be a novel marker for the diagnosis and follow-up of necrotizing enterocolitis,” Journal of Clinical Laboratory Analysis, vol. 28, no. 3, pp. 170–177, 2014.

[51] T. M. Benkoe, T. P. Mechtler, M. Weninger, M. Pones, W. Rehbandl, and D. C. Kasper, “Serum levels of interleukin-8 and gut-associated biomarkers in diagnosing necrotizing enterocolitis in preterm infants,” Journal of Pediatric Surgery, vol. 49, no. 10, pp. 1446–1451, 2014.

[52] T. Benkoe, C. Reck, M. Pones et al., “Interleukin-8 predicts 60-day mortality in premature infants with necrotizing enterocolitis,” Journal of Pediatric Surgery, vol. 49, no. 3, pp. 385–389, 2014.

[53] E. Fries and A. M. Blom, “Bikunin—not just a plasma proteinase inhibitor,” The International Journal of Biochemistry & Cell Biology, vol. 32, no. 2, pp. 125–137, 2000.

[54] B. A. Shah, A. Migliori, I. Kurihara, S. Sharma, Y. P. Lim, and J. Padbury, “Blood level of inter-alpha inhibitor proteins distinguishes necrotizing enterocolitis from spontaneous intestinal perforation,” The Journal of Pediatrics, vol. 180, pp. 135–140.e1, 2017.

[55] K. G. Sylvester, Z. J. Kastenberg, R. L. Moss et al., “Acylcarnitine profiles reflect metabolic vulnerability for necrotizing enterocolitis in newborns born premature,” The Journal of Pediatrics, vol. 181, pp. 80–85.e1, 2017.

[56] T. E. Schat, M. Schurink, M. E. van der Laan et al., “Near-infrared spectroscopy to predict the course of necrotizing enterocolitis,” PLoS One, vol. 11, no. 5, article e0154710, 2016.

[57] R. H. Hashem, Y. A. Mansi, N. S. Almasah, and A. Kosus, “Ischemia-modified albumin may be a novel marker for the diagnosis and follow-up of necrotizing enterocolitis,” Journal of Pediatrics, vol. 164, no. 5, pp. 170–177, 2014.

[58] A. Urboniene, A. Palepsaitis, R. Uktveris, and V. Barauskas, “Doppler ultrasound assessment of the splanchic circulation in preterms with neonatal sepsis at risk for necrotizing enterocolitis,” Journal of Ultrasound, vol. 20, no. 1, pp. 59–67, 2017.

[59] A. Urboniene, A. Palepsaitis, R. Uktveris, and V. Barauskas, “Doppler flowmetry of the superior mesenteric artery and portal vein: impact for the early prediction of necrotizing enterocolitis in neonates,” Pediatric Surgery International, vol. 31, no. 11, pp. 1061–1066, 2015.

[60] T. Al-Shargabi, D. Reich, R. Govindan et al., “Changes in autonomic tone in premature infants developing necrotizing enterocolitis,” Journal of Perinatology, vol. 36, no. 12, pp. 1156–1162, 2016.
enterocolitis,” *American Journal of Perinatology*, vol. 35, no. 11, pp. 1079–1086, 2018.

[60] K. K. Doheny, C. Palmer, K. N. Browning et al., “Diminished vagal tone is a predictive biomarker of necrotizing enterocolitis-risk in preterm infants,” *Neurogastroenterology and Motility*, vol. 26, no. 6, pp. 832–840, 2014.

[61] W. Zhou, W. Yuan, L. Huang, P. Wang, X. Rong, and J. Tang, "Association of neonatal necrotizing enterocolitis with myeloid differentiation-2 and GM2 activator protein genetic polymorphisms," *Molecular Medicine Reports*, vol. 12, no. 1, pp. 974–980, 2015.

[62] V. Sampath, H. Menden, D. Helbling et al., “SIGIRR genetic variants in premature infants with necrotizing enterocolitis,” *Pediatrics*, vol. 135, no. 6, pp. e1530–e1534, 2015.

[63] G. Terrin, L. Stronati, S. Cucchiara, and M. de Curtis, “Serum markers of necrotizing enterocolitis: a systematic review,” *Journal of Pediatric Gastroenterology and Nutrition*, vol. 65, no. 6, pp. e120–e132, 2017.

[64] K. G. Sylvester, X. B. Ling, G. Y. Liu et al., "A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants," *Gut*, vol. 63, no. 8, pp. 1284–1292, 2014.